Ultra-low doses of microRNAs restore a strong immune response in patients with Chronic Active Epstein-Barr Virus infection (CAEBV)
European Bio Immune (G)ene Medicine Association (EBMA), 29 rue Charles Sandherr, Colmar, France.
Research Article
International Journal of Scholarly Research and Reviews, 2024, 04(01), 001–008.
Article DOI: 10.56781/ijsrr.2024.4.1.0071
Publication history:
Received on 07 November 2023; revised on 02 January 2024; accepted on 05 January 2024
Abstract:
Chronic active Epstein-Barr Virus infection (CAEBV) is an abnormal response of the immune system to EBV infection, characterized by the absence of anti-EBNA (EBV Nuclear Antigens) IgG and associated with chronic fatigue and several immune related diseases. We present here an innovative therapeutic approach of CAEBV based on the use of ultra-low doses of non-coding RNAs (ncRNAs) involved in the host-virus interaction. We performed a retrospective study on 26 patients treated with our remedy. All the patients expect one developed positive EBNA IgG within eighteen months of starting treatment. Among the 25 cases that seroconverted, 75% report a significant improvement of their symptoms, especial of chronic fatigue. This study gives the proof of the efficiency of ultra-low doses of ncRNAs in restoring a strong immune response against EBV. More generally, this therapeutic approach can potentially be used in almost all pathologies.
Keywords:
Epstein-Barr Virus (EBV); Chronic fatigue; Non-coding RNA (ncRNA); MicroRNA (mRNA); Ultra-low doses; BioImmun(G)ene Medicine (BI(G)MED)
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0